To accelerate the time-to-market for therapeutics, leading biopharmaceutical companies are applying powerful B cell screening technologies like Cyto-Mine® that allow the highly efficient isolation of cells that produce potential therapeutic antibodies.
Download our new eBook to learn how researchers have screened and isolated rare antigen-specific B cells directly from large heterogeneous populations in just two days. By using Cyto-Mine®, researchers have overcome challenges in the antibody discovery process which are:
- Efficiency - screen the entire cell population
- Viability - maintain high levels of cell viability
- Speed - reduce total workflow timelines
- Measurement - semi-quantitative assays of antibody secretion
- Sensitivity & specificity - detect antibodies of interest
- Flexibility - adaptable assay design for specific needs